Binding mode of HIV-1 Gp41 with its inhibitor NB-2

Beijing Gongye Daxue Xuebao/Journal of Beijing University of Technology

Volumn 36, Issue 8, 2010, Pages 1118-1123

  Wang, Cun Xin ^a   Cong, Xiao Jing ^a   Kong, Ren ^a   Tan, Jian Jun ^a   Chen, Wei Zu ^a  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Binding mode; De novo drug design; HIV 1 gp41; Inhibitor; Molecular modeling

Indexed keywords

BINDING AFFINITIES; BINDING FREE ENERGY; BINDING MODES; DRUG DESIGN; ENERGY CALCULATION; FREE-ENERGY CALCULATIONS; HIV-1 GP41; INHIBITOR; MD SIMULATION; MOLECULAR DOCKING; MOLECULAR DYNAMIC SIMULATIONS; STRUCTURAL FEATURE; TRANS-MEMBRANE PROTEINS;

DESIGN; DOCKING; FREE ENERGY; MOLECULAR DYNAMICS; MOLECULAR MODELING; NIOBIUM COMPOUNDS;

BINDING ENERGY;

EID: 77956372248     PISSN: 02540037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. CHAN D C, FASS D, BERGER J M, et al. Core structure of gp41 from the HIV envelope glycoprotein[J]. Cell, 1997, 89(2): 263-273.
2. WEISSENHORN W, DESSEN A, HARRISON S C, et al. Atomic structure of the ectodomain from HIV-1 gp41[J]. Nature, 1997, 387(6631): 426-430.
3. LUBAN J. Absconding with the chaperone: essential cyclophilin-gag interaction in HIV-1 virions[J]. Cell, 1996, 87(7): 1157-1159.
4. FURUTA R A, WILD C T, WENG Y K, et al. Capture of an early fusion-active conformation of HIV-1 gp41[J]. Nature Structural Biology, 1998, 5(7): 612.
5. JIANG S B, LIN K, STRICK N, et al. HIV-1 inhibition by a peptide[J]. Nature, 1993, 365(6442): 113.
6. ECKERT D M, KIM P S. Mechanisms of viral membrane fusion and its inhibition[J]. Annual Review of Biochemistry, 2001, 70: 777-810.
7. JIANG S B, LIN K, ZHANG L, et al. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody[J]. Journal of Virological Methods, 1999, 80(1): 85-96.
8. DEBNATH A K, RADIGAN L, JIANG S B. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1[J]. Journal of Medicinal Chemistry, 1999, 42(17): 3203-3209.
9. JIANG S B, LU H, LIU S W, et al. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion[J]. Antimicrobial Agents and Chemotherapy, 2004, 48(11): 4349-4359.
10. MCCUNE J M, RABIN L B, FEINBERG M B, et al. Endoproteolytic cleavage of GP160 is required for the activation of human immunodeficiency virus[J]. Cell, 1988, 53(1): 55-67.
11. MORRIS G M, GOODSELL D S, HALLIDAY R S, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function[J]. Journal of Computational Chemistry, 1998, 19(14): 1639-1662.
12. JAIN A N. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine[J]. Journal of Medicinal Chemistry, 2003, 46(4): 499-511.
13. WANG J M, WOLF R M, CALDWELL J W, et al. Development and testing of a general amber force field[J]. Journal of Computational Chemistry, 2004, 25(9): 1157-1174.
14. WANG W, KOLLMAN P A. Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model[J]. Journal of Molecular Biology, 2000, 303(4): 567-582.
15. BAYLY C I, CIEPLAK P, CORNELL W D, et al. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges-the resp model[J]. Journal of Physical Chemistry, 1993, 97(40): 10269-10280.
16. DUAN Y, WU C, CHOWDHURY S, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations[J]. Journal of Computational Chemistry, 2003, 24(16): 1999-2012.
17. JORGENSEN W L, CHANDRASEKHAR J, MADURA J D, et al. Comparison of simple potential functions for simulating liquid water[J]. Journal of Chemical Physics, 1983, 79(2): 926-935.
18. RYCKAERT J P, CICCOTTI G, BERENDSEN H J C. Numerical-integration of cartesian equations of motion of a system with constraints-molecular-dynamics of N-alkanes[J]. Journal of Computational Physics, 1977, 23(3): 327-341.
19. MASSOVA I, KOLLMAN P A. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding[J]. Perspectives in Drug Discovery and Design, 2000, 18: 113-135.
20. WANG W, DONINI O, REYES C M, et al. Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions[J]. Annual Review of Biophysics and Biomolecular Structure, 2001, 30: 211-243.
21. HONIG B, NICHOLLS A. Classical electrostatics in biology and chemistry[J]. Science, 1995, 268(5214): 1144-1149.
22. HECHT J L, HONIG B, SHIN Y K, et al. Electrostatic potentials near-the-surface of dna-comparing theory and experiment[J]. Journal of Physical Chemistry, 1995, 99(19): 7782-7786.
23. SANNER M F, OLSON A J, SPEHNER J C. Reduced surface: an efficient way to compute molecular surfaces[J]. Biopolymers, 1996, 38(3): 305-320.
24. SITKOFF D, SHARP K A, HONIG B. Accurate calculation of hydration free-energies using macroscopic solvent models[J]. Journal of Physical Chemistry, 1994, 98(7): 1978-1988.
25. KUHN B, KOLLMAN P A. Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models[J]. Journal of Medicinal Chemistry, 2000, 43(20): 3786-3791.
26. BASHFORD D, CASE D A. Generalized born models of macromolecular solvation effects[J]. Annual Review of Physical Chemistry, 2000, 51: 129-152.
27. SIMONSON T. Macromolecular electrostatics: continuum models and their growing pains[J]. Current Opinion in Structural Biology, 2001, 11(2): 243-252.
28. WEISER J, SHENKIN P S, STILL W C. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO)[J]. Journal of Computational Chemistry, 1999, 20(2): 217-230.